beta 2 Microglobulin抗体;beta 2 Microglobulin Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of beta 2 Microglobulin in rat spleen, mouse spleen lysates using beta 2 Microglobulin antibody.    

  
  

•  

   

     Western blot analysis of beta 2 Microglobulin in Hela lysates using beta 2 Microglobulin antibody.    

  
  

Beta-2 microglobulin (B2M) is a small, non-glycosylated protein (11-12 kDa) that forms the invariant light chain of major histocompatibility complex (MHC) class I molecules, essential for antigen presentation to T-cells. It is constitutively expressed on nearly all nucleated cells and circulates freely in bodily fluids. B2M levels in serum or urine serve as biomarkers for various conditions, including renal dysfunction, inflammatory diseases, and certain cancers like multiple myeloma.

Antibodies targeting B2M are critical tools in research and diagnostics. Polyclonal and monoclonal anti-B2M antibodies are widely used to study MHC class I complex assembly, immune regulation, and cellular turnover. They enable detection of B2M via techniques such as Western blotting, immunohistochemistry (IHC), flow cytometry, and ELISA. In clinical settings, these antibodies aid in diagnosing renal tubular disorders (e.g., elevated urinary B2M indicates impaired proximal tubule reabsorption) and monitoring dialysis efficacy.

B2M’s role in amyloidosis, where it aggregates into fibrils in dialysis-related amyloidosis, has also driven antibody development for pathological studies. Additionally, B2M antibodies are employed in cancer research to explore MHC class I downregulation, a common immune evasion mechanism. Their specificity and versatility make B2M antibodies indispensable in both basic immunology and translational medicine.